Fig. 2From: Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agentsPrediction of nilotinib peak and trough plasma levels in prairie dogs upon multiple dosing. The dose groups include 7 mg/kg twice-daily, 20 mg/kg once-daily and 20 mg/kg twice-daily. Sold or dotted lines represent predicted profiles and the dots represented observed dataBack to article page